11-02/03 :: February / March 2011
nanotimes
Companies Facts
AG. Shares representing 56.1% of the shares of Win- terthur were tendered during the offer period. Toge- ther with shares purchased from shareholders outside of the offer process, the tender offer will result in 3M owning 85.3% of Winterthur’s shares.
http://www.leadcheck.com http://investor.3m.com
T
he U.S. Department of Energy (DOE) has awar- ded 3M $4.4 million as part of DOE’s SunShot
Initiative. SunShot aims to reduce the total costs of photovoltaic solar energy systems by about 75%, so that they are cost-competitive with other forms of energy without subsidies. SunShot calls for achieving this goal by the end of the decade. The sum of the 3M award is estimated at $4.4 million over three years. The goal of 3M’s project is to accelerate efforts toward further development and commercialization of 3M™ Ultra Barrier Solar Film. As part of the ini- tiative, 3M will collaborate with DOE’s National Re- newable Energy Laboratory (NREL) located near Den- ver, Colorado, to test the performance and durability of Ultra Barrier Solar Films. NREL recently confirmed moisture vapor transmission rates in the range of 2*10-5
– 8*10-5 g/m2 /day for 3M‘s current Ultra Barri-
er Film 9L product using its electrically based calcium moisture vapor transmission rate (MVTR) test.
http://www.3m.com
lithium ion batteries and systems, announced the pricing of an offering of 18,000,000 shares of com- mon stock at a price of $6.00 per share and an offering of $125,000,000 principal amount of con- vertible subordinated notes due 2016. The company has granted the underwriters a 30-day option to
A
123 Systems (NASDAQ:AONE), a developer and manufacturer of advanced Nanophosphate™
purchase up to an additional 2,700,000 shares of common stock, with respect to the stock offering, and up to $18,750,000 aggregate principal amount of the convertible notes, with respect to the converti- ble notes offering.
http://www.a123systems.com
a
ap Implantate AG (FSE: AAQ), a German medical technology company, totaled in the first-quarter
of the financial year 2011 sales of EUR6.5 million (previous year: EUR5.8 million), which was a 14% increase on the previous year’s figure. Consolidation of the two German R&D sites in Dieburg and Obern- burg was completed on March 15, 2011. aap plans to publish the full Q1 2011 on May 11, 2011.
http://www.aap.de
company, announced at the Molecular Medicine Tri- Conference its entrance in the rapidly growing next generation sequencing (NGS) market with the release of the NGS Collection for Pipeline Pilot. The NGS Collection, together with Accelrys’ industry-leading Pipeline Pilot™ data pipelining software, provide genomics researchers, bioinformaticians, and infor- mation technologists with the tools required to sim- plify NGS application development, to integrate and automate NGS data processing, and to accelerate the analysis and interpretation of the huge volumes of data generated by current DNA sequencing instru- ments.
A
Furthermore, Accelrys announced the new Accelrys Enterprise R&D Architecture, enabling industries and organizations that rely on scientific innovation to bring new products from lab to market more quickly
ccelrys, Inc. (NASDAQ: ACCL), the leading scientific informatics software and services
11
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95